Scott Mathis, APRN
Nurse Practitioner · Waycross, GANPI 1356535322
Payments from drug & device makers
Across 203 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$301
- AbbVie$299
- GSK$287
- Novo Nordisk$274
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$230
- Amgen$224
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$150%
- Food & beverage$3,549100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 20 | $301 |
| AbbVie | 18 | $299 |
| GSK | 19 | $287 |
| Novo Nordisk | 24 | $274 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $230 |
| Amgen | 15 | $224 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $208 |
| Boston Scientific | 3 | $184 |
| AstraZeneca | 10 | $180 |
| Antares Pharma, Inc. | 9 | $163 |
| Astellas Pharma US Inc | 8 | $162 |
| Dexcom, Inc. | 8 | $137 |
| Boehringer Ingelheim | 7 | $128 |
| Lilly USA, LLC | 6 | $98 |
| Exact Sciences | 3 | $81 |
| Indivior Inc. | 4 | $76 |
| Otsuka America Pharmaceutical, Inc. | 3 | $76 |
| Merck | 4 | $49 |
| Phathom Pharmaceuticals, Inc. | 3 | $49 |
| Bayer | 3 | $48 |
| Paratek Pharmaceuticals, Inc. | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Organogenesis Inc. | 1 | $26 |
| Noven Therapeutics, LLC | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Mckesson Medical-surgical, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL PAIN MANAGEMENT$123
- CAPLYTA$108
How this compares
$3,564 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 97 | $123,035 |
| EliquisApixaban | 170 | $120,909 |
| MounjaroTirzepatide | 41 | $43,136 |
| JanuviaSitagliptin Phosphate | 54 | $42,843 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 50 | $41,268 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $41,263 |
| JardianceEmpagliflozin | 47 | $36,649 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $36,484 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 37 | $26,517 |
| TrulicityDulaglutide | 23 | $25,749 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $24,818 |
| TradjentaLinagliptin | 24 | $19,385 |
| ProliaDenosumab | 11 | $18,872 |
| LinzessLinaclotide | 20 | $15,896 |
| Repatha SureclickEvolocumab | 19 | $13,949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $301 | $123,767190 claims |
| Novo NordiskOzempic | $274 | $123,03597 claims |
| MerckJanuvia, Janumet Xr, Janumet | $49 | $90,455115 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $128 | $82,551108 claims |
| Lilly USA, LLCMounjaro, Trulicity | $98 | $68,88464 claims |
| GSKTrelegy Ellipta | $287 | $41,26351 claims |
| AbbVieLinzess, Synthroid | $299 | $19,05689 claims |
| AmgenProlia | $224 | $18,87211 claims |
| AstraZenecaFarxiga, Symbicort | $180 | $16,00734 claims |
| Sanofi-aventis U.S. LLCLantus | $18 | $4,93735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.
Other nurse practitioner in Waycross
- Crystal LogsdonSavannah$566K
- Victor CzerkasijDalton$505K
- Kennon Mc CollumStockbridge$364K
- Pamela AllenRome$270K
- Tajuana BradleyJohns Creek$256K
- Janice McAlisterAtlanta$241K
- Jessica AdkinsSavannah$226K
- Laura ElledgeAtlanta$177K
- Afsha HussainiKennesaw$122K
- Elizabeth TyeAlbany$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.